At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,441 enrolled
Drug / intervention
TriVerityother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
In Brief
An observational study evaluating TriVerity for Respiratory Tract Infections and 5 related conditions. Completed, enrolled 1,441 participants across 26 sites in 2 countries.
Detailed Summary
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected sepsis of any cause.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
CountriesGreece, United States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartFeb 2020
Primary CompletionAug 2024
Study CompletionSep 2024
TodayJul 2026
First PostedSep 19, 2019
Enrollment StartFeb 28, 2020
Primary CompletionAug 6, 2024
Study CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.8 years ago
Interventions
TriVerityother
Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection